Foster City, CA and Mechelen, Belgium, 10 February 2021, 15.00 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences (NASDAQ: GILD) today announced the decision to ...
United Therapeutics Corporation UTHR announced that it has enrolled the first patient in the phase III TETON study which is evaluating Tyvaso for the treatment of adult patients with idiopathic ...
Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...
Please provide your email address to receive an email when new articles are posted on . Patients with idiopathic pulmonary fibrosis appear to have higher cumulative incidences of exertional and ...
Another drug included in a multi-billion dollar alliance between Gilead Sciences and Galapagos has been stymied by safety concerns. The partners announced Wednesday that they are stopping a late-stage ...
San Diego area startup Endeavor Biomedicines Inc. launched in January 2021, with a $62 million series A financing from Omega Funds, Longitude Capital and its own management team. The company is ...
San Diego area startup Endeavor Biomedicines Inc. launched in January 2021, with a $62 million series A financing from Omega Funds, Longitude Capital and its own management team. The company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results